uu.seUppsala universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper.
Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden;Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
Kings Coll London, Translat Oncol & Urol Res, London, England;Univ Southern Australia, Ctr Populat Hlth Res, Adelaide, SA, Australia.ORCID-id: 0000-0002-9798-1479
Univ Sykehuset Trondheim, Dept Urol, Sankt Olavs Hosp, Trondheim, Norway;NTNU Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Trondheim, Norway.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: BMJ Open, ISSN 2044-6055, E-ISSN 2044-6055, Vol. 9, nr 8Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction Overtreatment of localised prostate cancer is substantial despite increased use of active surveillance. No randomised trials help define how to monitor patients or when to initiate treatment with curative intent. Methods and analysis A randomised, multicentre, intervention trial designed to evaluate the safety of an MRI-based active surveillance protocol, with standardised triggers for repeated biopsies and radical treatment. The aim is to reduce overtreatment of prostate cancer. 2000 men will be randomly allocated to either surveillance according to current practice or to standardised triggers at centres in Sweden, Norway, Finland and the UK. Men diagnosed in the past 12 months with prostate cancer, <= T2a, prostate-specific antigen (PSA) <15ng/mL, PSA density <less than or equal to>0.2ng/mL/cc, any International Society of Urological Pathology (ISUP) grade 1 are eligible. Men with ISUP grade 2 in <30% of cores on systematic biopsy and <10mm cancer in one core on systematic or targeted biopsy are also eligible. Men diagnosed on systematic biopsy should have an MRI and targeted biopsies against Prostate Imaging and Reporting Data System V.2 3-5 lesions before inclusion. Identical follow-up in the two study arms: biannual PSA testing, yearly clinical examination and MRI every second year. In the experimental arm, standardised triggers based on MRI and PSA density elicit repeated biopsies. MRI and histopathological progression trigger radical treatment. Primary outcome measure is progression-free survival. Secondary outcome measures are cumulative incidence of metastatic disease, treatments with curative intent, pT3-4 at radical prostatectomy, switch to watchful waiting, prostate cancer mortality and quality of life. Inclusion started in October 2016 and in October 2018; 275 patients have been enrolled. Ethics and dissemination Ethical approval was obtained in each participating country. Results for the primary and secondary outcome measures will be submitted for publication in peer-reviewed journals. Trial registration number NCT02914873.

Ort, förlag, år, upplaga, sidor
BMJ PUBLISHING GROUP , 2019. Vol. 9, nr 8
Nyckelord [en]
active surveillance, MRI, prostate cancer, randomised trial
Nationell ämneskategori
Urologi och njurmedicin
Identifikatorer
URN: urn:nbn:se:uu:diva-401175DOI: 10.1136/bmjopen-2018-027860ISI: 000502537200134PubMedID: 31444180OAI: oai:DiVA.org:uu-401175DiVA, id: diva2:1383122
Forskningsfinansiär
Cancerfonden, 2016/466Cancerfonden, 2014/1275Vetenskapsrådet, 2016-00177Vetenskapsrådet, 2016-01293Tillgänglig från: 2020-01-07 Skapad: 2020-01-07 Senast uppdaterad: 2020-01-07Bibliografiskt granskad

Open Access i DiVA

fulltext(401 kB)45 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 401 kBChecksumma SHA-512
64b7cbf0304ff3f0f5d11fbed09f23f7f3281647e32067ab778769c1683fc6a43428e0510d2092c494deae907bed34b806310f3ade002020ee25e991c664fda0
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Ahlberg, Mats SteinholtzGarmo, HansHolmberg, LarsJohansson, EvaÅberg, Ulrika W. N.Bill-Axelson, Anna

Sök vidare i DiVA

Av författaren/redaktören
Ahlberg, Mats SteinholtzBeckmann, KerriGarmo, HansHolmberg, LarsJohansson, EvaÅberg, Ulrika W. N.Bill-Axelson, Anna
Av organisationen
Institutionen för kirurgiska vetenskaperUppsala kliniska forskningscentrum (UCR)Urologkirurgi
I samma tidskrift
BMJ Open
Urologi och njurmedicin

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 45 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 85 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf